Myriad Genetics, Inc. (NASDAQ:MYGN) Director Walter Phd Gilbert sold 7,500 shares of the stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $33.19, for a total transaction of $248,925.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Shares of Myriad Genetics, Inc. (NASDAQ MYGN) opened at $33.47 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.34 and a quick ratio of 2.06. The company has a market cap of $2,317.50, a PE ratio of 30.71, a P/E/G ratio of 2.13 and a beta of 0.25. Myriad Genetics, Inc. has a 12-month low of $15.15 and a 12-month high of $37.30.

Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings data on Tuesday, November 7th. The company reported $0.26 EPS for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.05. Myriad Genetics had a net margin of 13.28% and a return on equity of 9.54%. The firm had revenue of $190.20 million during the quarter, compared to the consensus estimate of $183.52 million. During the same quarter last year, the firm earned $0.23 earnings per share. The firm’s revenue was up 7.2% compared to the same quarter last year. equities analysts forecast that Myriad Genetics, Inc. will post 1.05 EPS for the current year.

Institutional investors have recently modified their holdings of the business. GHP Investment Advisors Inc. increased its holdings in Myriad Genetics by 11.1% in the third quarter. GHP Investment Advisors Inc. now owns 48,710 shares of the company’s stock valued at $1,762,000 after buying an additional 4,853 shares in the last quarter. Vanguard Group Inc. increased its holdings in Myriad Genetics by 0.9% in the second quarter. Vanguard Group Inc. now owns 6,307,738 shares of the company’s stock valued at $162,992,000 after buying an additional 56,708 shares in the last quarter. Airain ltd purchased a new position in Myriad Genetics in the second quarter valued at about $1,097,000. PDT Partners LLC purchased a new position in Myriad Genetics in the second quarter valued at about $8,481,000. Finally, Shell Asset Management Co. increased its holdings in Myriad Genetics by 34.3% in the third quarter. Shell Asset Management Co. now owns 54,867 shares of the company’s stock valued at $2,116,000 after buying an additional 14,021 shares in the last quarter.

Several brokerages have recently weighed in on MYGN. Zacks Investment Research downgraded shares of Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research note on Friday. Cowen reiterated a “hold” rating and set a $25.00 target price on shares of Myriad Genetics in a research note on Sunday, September 17th. Stephens reiterated an “overweight” rating and set a $40.00 target price (up previously from $36.00) on shares of Myriad Genetics in a research note on Friday, September 22nd. ValuEngine downgraded shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Finally, Leerink Swann reiterated a “market perform” rating and set a $31.00 target price on shares of Myriad Genetics in a research note on Monday, October 2nd. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $28.10.

COPYRIGHT VIOLATION WARNING: “Insider Selling: Myriad Genetics, Inc. (MYGN) Director Sells $248,925.00 in Stock” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/insider-selling-myriad-genetics-inc-mygn-director-sells-248925-00-in-stock/1771160.html.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.